Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

322.35DKK
10:27am EDT
Change (% chg)

kr.3.35 (+1.05%)
Prev Close
kr.319.00
Open
kr.318.20
Day's High
kr.322.95
Day's Low
kr.317.80
Volume
911,536
Avg. Vol
2,460,889
52-wk High
kr.349.70
52-wk Low
kr.265.15

Latest Key Developments (Source: Significant Developments)

FDA Approves New Treatment For Pediatric Patients With Type 2 Diabetes
Monday, 17 Jun 2019 03:26pm EDT 

June 17 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR PEDIATRIC PATIENTS WITH TYPE 2 DIABETES.U.S. FDA - APPROVED VICTOZA (LIRAGLUTIDE) INJECTION FOR TREATMENT OF PEDIATRIC PATIENTS 10 YEARS OR OLDER WITH TYPE 2 DIABETES.FDA - APPROVAL OF VICTOZA WAS GRANTED TO NOVO NORDISK.U.S. FDA - PRESCRIBING INFORMATION FOR VICTOZA INCLUDES BOXED WARNING TO ADVISE ABOUT INCREASED RISK OF THYROID C-CELL TUMORS.  Full Article

Novo Nordisk Submits Oral Semaglutide For EU Regulatory Approval
Friday, 26 Apr 2019 04:58am EDT 

April 26 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK FILES FOR EU REGULATORY APPROVAL OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES.SAYS ORAL SEMAGLUTIDE HAS NOW BEEN SUBMITTED FOR REGULATORY APPROVAL IN US, EU AND CANADA.  Full Article

Novo Nordisk Announces Reduction Of Share Capital
Wednesday, 24 Apr 2019 12:27pm EDT 

April 24 (Reuters) - Novo Nordisk A/S ::Novo Nordisk A/S - REDUCTION OF SHARE CAPITAL.CO CANCELLED B SHARES AT A NOMINAL VALUE OF DKK 10,000,000.REGISTERED IMPLEMENTATION OF REDUCTION OF SHARE CAPITAL WITH DANISH BUSINESS AUTHORITY AND CANCELLED B SHARES AT NOMINAL VALUE OF DKK 10 MILLION.AT CO'S ANNUAL GENERAL MEETING ON 21 MARCH, IT WAS DECIDED TO REDUCE CO'S B SHARE CAPITAL FROM DKK 382.5 MILLION TO DKK 372.5 MILLION.REDUCTION OF SHARE CAPITAL WILL NOT AFFECT NOVO NORDISK'S SHARE REPURCHASE PROGRAMME WHICH WILL CONTINUE AS PREVIOUSLY ANNOUNCED.AFTER REDUCTION CO'S SHARE CAPITAL IS NOMINALLY DKK 480 MILLION, DIVIDED INTO A SHARE OF NOMINALLY DKK 107,487,200, B SHARE OF NOMINALLY DKK 372,512,800.  Full Article

Novo and Gilead Intent To Initiate Clinical Collaboration in NASH
Friday, 12 Apr 2019 04:01am EDT 

April 12 (Reuters) - Novo Nordisk NOVOB.CO::GILEAD SCIENCES AND NOVO NORDISK ANNOUNCE INTENT TO INITIATE A CLINICAL COLLABORATION IN NASH.THE COMPANIES INTEND TO COLLABORATE ON A CLINICAL TRIAL COMBINING COMPOUNDS FROM THEIR RESPECTIVE PIPELINES IN NONALCOHOLIC STEATOHEPATITIS (NASH).THE COMPANIES ARE ALSO EXPLORING THE POTENTIAL TO COLLABORATE ON PRECLINICAL RESEARCH TO ADVANCE UNDERSTANDING OF THE DISEASE.CILOFEXOR AND FIRSOCOSTAT, ALONE OR IN COMBINATION, ARE INVESTIGATIONAL COMPOUNDS AND ARE NOT APPROVED BY THE U.S. FOOD & DRUG ADMINISTRATION (FDA) OR ANY OTHER REGULATORY AUTHORITY.  Full Article

Novo Nordisk To Invest DKK 650 Million In Denmark Production Facilities
Friday, 29 Mar 2019 07:03am EDT 

March 29 (Reuters) - NOVO NORDISK A/S SAYS ::SAYS INVESTS DKK 650 MILLION IN UPGRADINGAND EXPANDING PRODUCTION FACILITIES IN KALUNDBORG.THE FACILITIES IN QUESTION ARE CURRENTLY MANUFACTURING A RANGE OF PRODUCTS FOR DIABETES TREATMENT AND WILL BE REBUILT TO ALLOW FOR FUTURE PRODUCTION OF THE NEXT GENERATION OF PRODUCTS.SAYS THE PROJECTS ARE EXPECTED TO BE COMPLETED IN 2020.SINCE THE TURN OF THE MILLENNIUM ALONE, NOVO NORDISK HAS INVESTED MORE THAN DKK 15 BILLION IN KALUNDBORG.  Full Article

Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva
Monday, 18 Mar 2019 07:02am EDT 

March 18 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK SETTLES U.S. PATENT LITIGATION CASE ON VICTOZA® (LIRAGLUTIDE) WITH TEVA.SAYS TEVA IS LICENSED TO LAUNCH A GENERIC VERSION OF VICTOZAAS OF 22 DECEMBER 2023.UNDER CERTAIN CIRCUMSTANCES TEVA COULD LAUNCH A GENERIC VERSION OF VICTOZA(®) EARLIER, BUT NOT BEFORE 22 MARCH 2023, UNLESS VICTOZA(®) PATENTS ARE NO LONGER IN FORCE OR THERE IS ANOTHER GENERIC VERSION OF VICTOZA(®) ON MARKET.SAYS IF NOVO NORDISK IS GRANTED SIX MONTHS PAEDIATRIC EXTENSION FOR VICTOZA(®), ALL ABOVE-MENTIONED TIMELINES WILL BE EXTENDED BY SIX MONTHS.SAYS - AGREEMENT IS SUBJECT TO REVIEW BY US FEDERAL TRADE COMMISSION AND US DEPARTMENT OF JUSTICE.  Full Article

Novo Nordisk Files For Fiasp Label Update In US, Europe
Friday, 1 Mar 2019 07:00am EST 

March 1 (Reuters) - NOVO NORDISK A/S ::FILES FOR A LABEL UPDATE FOR FIASP® TO THE EMA AND THE FDA SEEKING APPROVAL FOR USE IN CHILDREN AND ADOLESCENTS.SAYS WE ANTICIPATE A RESPONSE FROM EMA LATER THIS YEAR, AND FROM FDA IN EARLY 2020.  Full Article

Novo Nordisk Proposes Heineken CFO Joins Board
Friday, 22 Feb 2019 02:02am EST 

Feb 22 (Reuters) - Novo Nordisk A/S ::SAYS BOARD OF DIRECTORS PROPOSES RE-ELECTION OF ALL CURRENT BOARD MEMBERS.SAYS BOARD OF DIRECTORS PROPOSES ELECTION OF LAURENCE DEBROUX AT ANNUAL GENERAL MEETING.SAYS LAURENCE DEBROUX IS GROUP CHIEF FINANCIAL OFFICER AND MEMBER OF EXECUTIVE BOARD OF HEINEKEN.  Full Article

Abbott And Novo Nordisk Partner To Provide Integrated Digital Solution To People With Diabetes Using Insulin
Wednesday, 20 Feb 2019 09:00am EST 

Feb 20 (Reuters) - Abbott Laboratories ::ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN.ABBOTT - PARTNERSHIP TO INTEGRATE INSULIN DOSE DATA FROM NOVO NORDISK CONNECTED PENS INTO DIGITAL HEALTH TOOLS COMPATIBLE WITH FREESTYLE LIBRE SYSTEM.  Full Article

Novo Nordisk Receives US FDA Approval Of Esperoct (Turoctocog Alfa Pegol, N8-Gp)
Tuesday, 19 Feb 2019 12:29pm EST 

Feb 19 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK RECEIVES US FDA APPROVAL OF ESPEROCT® (TUROCTOCOG ALFA PEGOL, N8-GP).APPROVED BIOLOGICS LICENSE APPLICATION FOR ESPEROCT(®) FOR TREATMENT OF ADULTS AND CHILDREN WITH HAEMOPHILIA A.DUE TO THIRD-PARTY IP AGREEMENTS, NOVO NORDISK WILL NOT BE ABLE TO LAUNCH ESPEROCT(®) BEFORE 2020 IN USA.  Full Article

BRIEF-Novo Nordisk: PIONEER 6 Trial Achieved Its Primary Endpoint

* SAID ON TUESDAY THE PIONEER 6 TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE